Hatch-Waxman Safe Harbor Could Get Supreme Court Review
This article was originally published in The Pink Sheet Daily
Executive Summary
High court invites the Solicitor General to submit a brief after GlaxoSmithKline seeks review of a Federal Circuit finding that the safe harbor provision barring infringement claims only pertains to actions to obtain generic approvals; the ruling held GSK’s participation in a study on immunization schedules infringed Classen patents.
You may also be interested in...
Hatch-Waxman Safe Harbor Ruling Wrong In GSK Case, Solicitor General Says, But Should Not Be Reviewed
Supreme Court should not take up GlaxoSmithKline v. Classen given the Federal Circuit’s subsequent decision in Momenta v. Amphastar, the Solicitor General argues; Momenta plans to seek review of its case.
Hatch-Waxman “Safe Harbor” Could Face Two-Front Battle In Supreme Court
Momenta plans to seek high court review of the scope of the “Bolar Amendment” in an enoxaparin patent dispute; activity in a second “safe harbor” case at the Supreme Court is expected to resume now that the appeals court proceedings in Momenta v. Amphastar have concluded.
Hatch-Waxman “Safe Harbor” Ruling Threatens Compound Patents, Momenta Says
Enoxaparin marketing partners Momenta and Sandoz seek rehearing en banc of an appellate panel’s decision that broadly interpreted the scope of the so-called “Bolar Amendment.” Amphastar and Watson, whom the panel said were protected from patent infringement claims, oppose the request.